Abstract:Objective: Alkaline phosphatase (ALP) is used as a biomarker to monitor the chronic kidney disease-mineral bone disorder (CKD-MBD) and high levels of parathyroid hormone (PTH) that were reported to be related to increased mortality in CKD patients. Therefore, we conducted this longitudinal cohort study to evaluate the relations between ALP and intact PTH (iPTH) and the associations with all-cause and cardiovascular mortality in peritoneal dialysis (PD) patients. Methods: In 1276 incident PD patients (median age 50 years, 56% males), baseline serum ALP, iPTH, and metabolic biomarkers potentially linked to CKD-MBD were analyzed in relation to mortality during follow-up period of up to 60 months. All-cause and cardiovascular mortality risk of ALP and iPTH were analyzed with competing-risks regression models with transplantation as competing risk adjusting for all covariates. Results: After adjustments for confounders by logistic regression model, older age, higher change level to levels of iPTH, S-albumin, calcium, alanine transaminase (ALT), and lower level of phosphorus were associated with higher ALP level (>79 U/L), and female gender, non-diabetes mellitus, younger age, lower calcium, higher ALT, total bilirubin, phosphorus, and ALP were associated with higher iPTH level (>300 pg/mL). During 60 months (median 44 months) of follow-up, the all-cause mortality rate was 16%, and 91 (46%) of the 199 deaths were caused by cardiovascular disease. In competing-risks regression analysis, "high ALP + low iPTH" was independently associated with all-cause and cardiovascular mortality after adjustment for age, gender, presence of diabetes, and cardiovascular disease, the calendar year of recruitment and vitamin D therapy in PD patients. The subhazard ratio (sHR) of group "high ALP + low iPTH" was 1.96 times and 3.35 times higher than sHR of group "low ALP + high iPTH" for all-cause mortality and cardiovascular mortality, respectively. Conclusions: The combination of high ALP and low iPTH was independently associated with increased all-cause and cardiovascular mortality in PD patients, suggesting that ALP and iPTH have the potential to predict clinical outcomes and might be useful risk assessment tools in PD patients. Further studies exploring the observed association between combination of ALP with iPTH and mortality are warranted.

Phospholipid transfer protein in hemodialysis patients.

High Plasma Phospholipid Transfer Protein Levels As a Risk Factor for Coronary Artery Disease

Pltp Activity is A Risk Factor for Subsequent Cardiovascular Events in Cad Patients under Statin Therapy: the Atherogene Study

Serum Phospholipid Transfer Protein Activity after a High Fat Meal in Patients with Insulin-Treated Type 2 Diabetes

Plasma PLTP Activity is Inversely Associated with HDL-C Levels

The Effect of Phospholipid Transfer Protein on Lipoprotein Metabolism and Atherosclerosis

Targeted Mutation of Plasma Phospholipid Transfer Protein Gene Markedly Reduces High-Density Lipoprotein Levels.

Abstract 330: Liver-Specific Phospholipids Transfer Protein Activity Has Significant Contribution in Hepatocyte Apob-Containing Lipoprotein Production and in Plasma Lipoprotein Metabolism

High PLTP Activity is Associated with Depressed Left Ventricular Systolic Function.

Macrophage Phospholipid Transfer Protein Contributes Significantly To Total Plasma Phospholipid Transfer Activity And Its Deficiency Leads To Diminished Atherosclerotic Lesion Development

Increased Atherosclerotic Lesions in ApoE Mice with Plasma Phospholipid Transfer Protein Overexpression

Elevated Baseline Plasma Phospholipid Protein (PLTP) Levels Are an Independent Predictor of Long-Term All-Cause Mortality in Patients with Diabetes Mellitus and Known or Suspected Coronary Artery Disease.

Effect of phospholipid transfer protein on plasma sphingosine-1-phosphate

PLTP activity inversely correlates with CAAD: effects of PON1 enzyme activity and genetic variants on PLTP activity

Phospholipid Transfer Protein Destabilizes Mouse Atherosclerotic Plaque.

Role of Phospholipid Transfer Protein in High-Density Lipoprotein– Mediated Reverse Cholesterol Transport

Phospholipid Transfer Protein Deficiency Decreases the Content of S1P in HDL via the Loss of its Transfer Capability

Phospholipid Transfer Protein Deficiency Protects Circulating Lipoproteins from Oxidation Due to the Enhanced Accumulation of Vitamin E

The role of plasma lipid transfer proteins in lipoprotein metabolism and atherogenesis D.M. is supported by a grant from the Philippe Foundation. Published, JLR Papers in Press, November 20, 2008.

The Role of Phospholipid Transfer Protein in the Development of Atherosclerosis

High Alkaline Phosphatase and Low Intact Parathyroid Hormone Associate with Worse Clinical Outcome in Peritoneal Dialysis Patients